Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy and tolerability of immune checkpoint inhibitors in elderly patients with MSI/dMMR gastrointestinal cancers and impact of toxicities on efficacy: The immunoMSI cohort.
Authors
Leah Mailly-Giacchetti
Sorbonne Université, Department of Medical Oncology, Saint-Antoine Hospital, AP-HP, Paris, France;
Leah Mailly-Giacchetti , Raphael Colle , Daniel Lopez-Trabada Ataz , Alex Duval , Thierry Andre , Romain Cohen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Symptoms, Toxicities, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 795)
DOI
10.1200/JCO.2023.41.4_suppl.795
Abstract #
795
Poster Bd #
M10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2023 ASCO Genitourinary Cancers Symposium
Safety and efficacy of immune checkpoint inhibitors (ICI) in advanced penile squamous cell carcinoma (PeCa): An international study from the Global Society of Rare Genitourinary Tumors (GSRGT).
First Author: Talal El Zarif
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Prognostic impact of immune-related adverse events on survival outcomes in metastatic gastrointestinal cancer: A single-institutional experience.
First Author: Olisaemeka Ogbue
Poster
2022 ASCO Annual Meeting
Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.
First Author: Lyndsey L Prather